Liverpool ChiroChem secures £2.25m investment
Liverpool ChiroChem has secured £2.25m in a funding round led by the VC firms Deepbridge Capital and Praetura Ventures.
Liverpool ChiroChem (LCC), the developer and manufacturer of chemical components that are critical to the research and development of new drugs, also saw investment from NPIF – Maven Equity Finance, managed by Maven and part of the Northern Powerhouse Investment Fund.
LCC is a chemistry-based contract research organisation (CRO) that produces and supplies chiral small molecules to the global pharmaceutical and biotech research and development sector. Its goal is to accelerate the discovery and development of new drugs across multiple therapeutic areas including dementia, cancer and respiratory conditions.
Led by Dr Paul Colbon, the business supports a global customer base from its research and development headquarters in Liverpool and its manufacturing facility in Taizhou, China. Recent client wins include two of the world’s top five pharmaceutical companies.
LCC has also announced a number of senior appointments and the launch of a new scientific advisory board that will help maximise the commercial impact of the chemical components LCC develops. With more than 25 years’ experience in senior management across multiple sectors, Stuart Noble joins the business as CFO and will work alongside Dr Paul Colbon and his management team on the next stage of LCC’s growth strategy. They will be supported Dr Jason Tierney, who has joined to chair the scientific advisory board. Jason played a leading role in the design of multiple screening libraries for companies such as GSK, that allow new drugs to be discovered and developed.
